Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether continuous clopidogrel dose adjustment targeted after platelet function testing improves outcomes during 12 months of follow-up in acute coronary syndrome patients treated with coronary artery stenting and with determined high platelet reactivity on clopidogrel.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zagreb
• Collaborators: Clinical Hospital Centre Zagreb; Ministry of Science, Education and Sport, Republic of Croatia
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• acute coronary syndrome patients treated with successful PCI

• age 18-80 years

• determined high on-treatment platelet reactivity

Exclusion Criteria:

• continuous postinterventional glycoprotein (GP) IIbIIIa receptor inhibitor infusion

• thrombocytopenia (<150x109/L)

• significant renal insufficiency (creatinine>200 µmol/L)

• anemia (Htc<30%)

• hemorrhagic diathesis

• history of intracranial bleeding or ischemic cerebrovascular insult 6 months before

• major operation 6 weeks before

• concomitant chronic anticoagulation therapy

• age <18 years and >80 years